The aggregation process of α-synuclein, a protein closely associated with Parkinson's disease, is highly sensitive to sequence variations. It is therefore of great importance to understand the factors that define the aggregation propensity of specific mutational variants as well as their toxic behavior in the cellular environment. In this context, we investigated the extent to which the aggregation behavior of α-synuclein can be altered to resemble that of β-synuclein, an aggregation-resistant homologue of α-synuclein not associated with disease, by swapping residues between the two proteins. Because of the vast number of possible swaps, we have applied a rational design procedure to single out a mutational variant, called α2β, in which two short stretches of the sequence in the NAC region have been replaced in α-synuclein from β-synuclein. We find not only that the aggregation rate of α2β is close to that of β-synuclein, being much lower than that of α-synuclein, but also that α2β effectively changes the cellular toxicity of α-synuclein to a value similar to that of β-synuclein upon exposure of SH-SY5Y cells to preformed oligomers. Remarkably, control experiments on the corresponding mutational variant of β-synuclein, called β2α, confirmed that the mutations that we have identified also shift the aggregation behavior of this protein toward that of α-synuclein. These results demonstrate that it is becoming possible to control in quantitative detail the sequence code that defines the aggregation behavior and toxicity of α-synuclein. © 2012 American Chemical Society.

A rationally designed six-residue swap generates comparability in the aggregation behavior of α-synuclein and β-synuclein / Roodveldt, C.; Andersson, A.; De Genst, E. J.; Labrador-Garrido, A.; Buell, A. K.; Dobson, C. M.; Tartaglia, G. G.; Vendruscolo, M.. - In: BIOCHEMISTRY. - ISSN 0006-2960. - 51:44(2012), pp. 8771-8778. [10.1021/bi300558q]

A rationally designed six-residue swap generates comparability in the aggregation behavior of α-synuclein and β-synuclein

Tartaglia G. G.;Vendruscolo M.
2012

Abstract

The aggregation process of α-synuclein, a protein closely associated with Parkinson's disease, is highly sensitive to sequence variations. It is therefore of great importance to understand the factors that define the aggregation propensity of specific mutational variants as well as their toxic behavior in the cellular environment. In this context, we investigated the extent to which the aggregation behavior of α-synuclein can be altered to resemble that of β-synuclein, an aggregation-resistant homologue of α-synuclein not associated with disease, by swapping residues between the two proteins. Because of the vast number of possible swaps, we have applied a rational design procedure to single out a mutational variant, called α2β, in which two short stretches of the sequence in the NAC region have been replaced in α-synuclein from β-synuclein. We find not only that the aggregation rate of α2β is close to that of β-synuclein, being much lower than that of α-synuclein, but also that α2β effectively changes the cellular toxicity of α-synuclein to a value similar to that of β-synuclein upon exposure of SH-SY5Y cells to preformed oligomers. Remarkably, control experiments on the corresponding mutational variant of β-synuclein, called β2α, confirmed that the mutations that we have identified also shift the aggregation behavior of this protein toward that of α-synuclein. These results demonstrate that it is becoming possible to control in quantitative detail the sequence code that defines the aggregation behavior and toxicity of α-synuclein. © 2012 American Chemical Society.
2012
Amino acid sequence; amino Acid substitution; cell survival; humans; molecular sequence data; sequence alignment; tumor cells, cultured; alpha-Synuclein; beta-Synuclein; protein structure, quaternary
01 Pubblicazione su rivista::01a Articolo in rivista
A rationally designed six-residue swap generates comparability in the aggregation behavior of α-synuclein and β-synuclein / Roodveldt, C.; Andersson, A.; De Genst, E. J.; Labrador-Garrido, A.; Buell, A. K.; Dobson, C. M.; Tartaglia, G. G.; Vendruscolo, M.. - In: BIOCHEMISTRY. - ISSN 0006-2960. - 51:44(2012), pp. 8771-8778. [10.1021/bi300558q]
File allegati a questo prodotto
File Dimensione Formato  
Roodveldt_ Rationally_2020.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 2.4 MB
Formato Adobe PDF
2.4 MB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1451746
Citazioni
  • ???jsp.display-item.citation.pmc??? 12
  • Scopus 23
  • ???jsp.display-item.citation.isi??? 23
social impact